Categories: News

Semler Scientific to Present at Upcoming Investor Conferences

SANTA CLARA, Calif., Aug. 26, 2021 /PRNewswire/ — Semler Scientific, Inc. (OTCQB: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that Chief Executive Officer Doug Murphy-Chutorian, M.D. and Chief Marketing Officer Dennis Rosenberg will participate in the following investor conferences that are being held virtually in September.

Colliers 2021 Institutional Investor Conference
Date: September 9, 2021
Format: One-on-one investor meetings

H.C. Wainwright & Co. 23rd Annual Global Investment Conference
Date: September 13, 2021
Format: On-demand corporate presentation is available beginning at 7:00 AM ET on September 13, 2021; one-on-one meetings. The webcast of the presentation will be archived for 90 days and may be accessed through the following link: https://journey.ct.events/view/557ff96b-03cc-487d-a12a-85504df11403.

2021 Best Ideas Growth (BIG5) Conference hosted by Lake Street Securities
Date: September 14 & 15, 2021
Format: One-on-one meetings

About Semler Scientific, Inc.:
Semler Scientific, Inc. is a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. Semler Scientific’s mission is to develop, manufacture and market innovative products and services that assist its customers in evaluating and treating chronic diseases. Semler Scientific commercially launched its first patented and U.S. Food and Drug Administration, or FDA, cleared product in 2011, and received FDA 510(k) clearance for QuantaFlo®, the next generation version of this product, in 2015. QuantaFlo® is a rapid point-of-care test that measures arterial blood flow in the extremities to aid in the diagnosis of peripheral arterial disease. QuantaFlo® is used by Semler Scientific’s customers to more comprehensively evaluate their patients for risk of heart attacks and strokes. Semler Scientific believes it is positioned to provide valuable information to its insurance company and physician customers, which in turn permits them to better guide patient care. Additional information about Semler Scientific can be found at semlerscientific.com.

INVESTOR CONTACT:
Susan A. Noonan
S.A. Noonan Communications
susan@sanoonan.com
212 966 3650

View original content:https://www.prnewswire.com/news-releases/semler-scientific-to-present-at-upcoming-investor-conferences-301363322.html

SOURCE Semler Scientific, Inc.

Staff

Recent Posts

Healthcare IT Market Set to More Than Double by 2030 Growing at 15.24% CAGR, Reports Mordor Intelligence

HYDERABAD, India, December 15, 2025 /PRNewswire/ -- According to Mordor Intelligence, the healthcare IT market …

48 minutes ago

Piramal Pharma Solutions Demonstrates Commitment to Excellence with Outstanding Net Promoter Score

Piramal Pharma Solutions recently achieved a net promoter score (NPS) of 55, far surpassing industry…

48 minutes ago

Amphastar Announces FDA Approval for Teriparatide Injection

RANCHO CUCAMONGA, CA / ACCESS Newswire / December 15, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)…

48 minutes ago

Multi Sciences Elevates Research Access with Global Bioz Badges Roll-out

PALO ALTO, CALIFORNIA / ACCESS Newswire / December 15, 2025 / Bioz, Inc., the leading…

49 minutes ago

Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics

GENEVA, SWITZERLAND / ACCESS Newswire / December 15, 2025 / MindMaze Therapeutics Holding SA (SIX:MMTX)…

4 hours ago

Vaxxas Secures TGA Licence to Manufacture Therapeutic Goods

Milestone enables GMP manufacturing to accelerate clinical trials and transform global vaccine delivery BRISBANE, Australia…

22 hours ago